How I treat... Psoriasis comorbidities by the adalimumab (Humira®) anti-TNFα biological;Comment je traite... Des comorbidités du psoriasis par la biothérapie anti-TNFα de type adalimumab (Humira®)

Revue Medicale de Liege

Volumn 65, Issue 10, 2010, Pages 545-548

  Pierard Franchimont C ^a,b   Henry, F ^a,b   Szepetiuk, G ^b   Pierard G E ^a,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre Hospitalier Hutois   (Belgium)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Adalimumab; Biologicals; Cardiovascular disease; Inflammatory bowel disease; Metabolic syndrome; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB;

ALOPECIA; COMORBIDITY; HUMAN; METABOLIC SYNDROME X; PSORIASIS; PSORIATIC ALOPECIA; PSORIATIC ARTHRITIS; REVIEW;

ALOPECIA; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CROHN DISEASE; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049453481     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Christophers E. - Comorbidities in psoriasis. Clin Dermatol, 2007, 25, 529-534.
2. Ali Y, Tom BDM, Schentag CT, et al. - Improved survival in psoriatic arthritis (PsA) with calendar time. Arthritis Rheum, 2007, 56, 2708-2714. (Pubitemid 47237289)
3. Gelfand JM, Troxel AB, Lewis JD, et al. - The risk of mortality in patients with psoriasis : results from a population-based study. Arch Dermatol, 2007, 143, 1493-1499. (Pubitemid 350277763)
4. Piérard-Franchimont C, Quatresooz P, Paquet P, et al. - Panoplies des thérapies ciblées par anticorps monoclonaux en dermatologie. Actualité et prospectives. Rev Med Liège, 2009, 64, 334-338.
5. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. - The cytokine and chemokine network in psoriasis. Clin Dermatol, 2007, 25, 568-573.
6. Collamer A, Guerrero K, Henning J, et al. - Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Am Coll Rheum, 2008, 58, 996-1001. (Pubitemid 351990997)
7. Saurat JH, Stingl G, Dubertret L, et al. - Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol, 2008, 158, 558-566.
8. Tyring S, Gordon KB, Poulin Y, et al. - Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol, 2007, 143, 719-726. (Pubitemid 46955730)
9. Piérard-Franchimont C, Piérard GE. - Teloptosis, a turning point in hair shedding biorhythms. Dermatology, 2001, 230, 115-117.
10. Piérard-Franchimont C, Petit L, Loussouarn G, et al. - The hair eclipse phenomenon : sharpening the focus on the hair cycle chronobiology. Int J Cosmet Sci, 2003, 25, 295-299. (Pubitemid 38005441)
11. Gisondi P, Girolomoni G, Sampogna F, et al. - Prevalence of psoriatic arthritis and joints complaints in a large population of Italian patients hospitalized for psoriasis. Eur J Dermatol, 2005, 15, 279-283. (Pubitemid 41020858)
12. Kana D, Stafford L, Bresniham B, et al. - A prospective, clinical and radiological study of early psoriatic arthritis : an early synovitis clinic experience. Rheumatology, 2003, 42, 1460-1468. (Pubitemid 37508919)
13. Duffin KC, Wong B, Horn EJ, et al. - Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol, 2009, 60, 604-608.
14. Mease PJ, Ory P, Sharp JT, et al. - Adalimumab for long-term treatment of psoriatic arthritis : 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis, 2009, 68, 702-709.
15. Mensah KA, Schwarz EM, Ritchlin CT. - Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep, 2008, 10, 311-317.
16. Gisondi P, Tinazzi I El-Dalati G, et al. - Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy : a hospital-based case-control study. Ann Rheum Dis, 2008, 67, 26-30.
17. Cohen AD, Dreiher J, Birkenfeld S. - Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol, 2009, 23, 561-565.
18. Bosani M, Ardizzone S, Porro GB. - Biologic targeting in the treatment of inflammatory bowel diseases. Biologics, 2009, 3, 77-97.
19. Gottlieb AB, Dann F, Menter A. - Psoriasis and the metabolic syndrome. J Drugs Dermatol, 2008, 7, 563-572.
20. Rorive M, De Flines J, Paquot N, et al. - Prise en charge d'une personne obèse avec syndrome métabolique. Rev Med Liège, 2009, 64, 651-656.
21. Gisondi P, Tessari G, Conti A, et al. - Prevalence of metabolic syndrome in patients with psoriasis : a hospital-based case-control study. Br J Dermatol, 2007, 157, 68-73.
22. Saraceno R, Schipani C, Mazzota A, et al. - Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res, 2008, 57, 290-295.
23. Rondinone CM. - Adipocyte-derived hormones, cytokines, and mediators. Endocrine, 2006, 29, 81-90.
24. Huvers FC, Popa C, Netera MG, et al. - Improved insulin sensitivity by anti-TNF-alpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis, 2007, 66, 558-559.
25. Wu JJ, Tsai TF. - Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol, 2008, 144, 1403-1404.
26. Shramm C, Schneider A, Marx A, Lohse AW. - Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol, 2008, 46, 1369-1371.
27. Kimball AB, Robinson D Jr, Wu Y, et al. - Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology, 2008, 217, 27-37.
28. Gisondi P, Fantin F, Del Giglio M, et al. - Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology, 2009, 218, 110-113.
29. Ledingham J, Deighton C. - Update on the British Society for Rheumatology guidelines for prescribing TNFα-alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology, 2005, 44, 157-163.
30. Collamer AN, Guerrero KG, Henning JS, et al. - Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy : a literature review and potential mechanisms of action. Arthritis Rheum, 2008, 59, 996-1001.
31. Nestle FO, Conrad C, Tun-Kyi A, et al. - Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med, 2005, 202, 135-143.
32. Piérard-Franchimont C, Piérard GE. - Réactions cutanées indésirables des traitements par anticorps monoclonaux. Rev Med Liège, 2009, 64, 339-346.